KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adaptive Biotechnologies (ADPT) Change in Accured Expenses (2018 - 2025)

Adaptive Biotechnologies' Change in Accured Expenses history spans 8 years, with the latest figure at $1.2 million for Q4 2025.

  • For Q4 2025, Change in Accured Expenses fell 72.68% year-over-year to $1.2 million; the TTM value through Dec 2025 reached $665000.0, down 0.89%, while the annual FY2025 figure was $665000.0, 0.89% down from the prior year.
  • Change in Accured Expenses for Q4 2025 was $1.2 million at Adaptive Biotechnologies, down from $5.9 million in the prior quarter.
  • Across five years, Change in Accured Expenses topped out at $10.5 million in Q4 2022 and bottomed at -$15.9 million in Q1 2023.
  • The 5-year median for Change in Accured Expenses is $786000.0 (2024), against an average of $349000.0.
  • The largest annual shift saw Change in Accured Expenses tumbled 150.71% in 2023 before it skyrocketed 10093.22% in 2025.
  • A 5-year view of Change in Accured Expenses shows it stood at -$1.6 million in 2021, then soared by 767.3% to $10.5 million in 2022, then plummeted by 49.3% to $5.3 million in 2023, then dropped by 20.13% to $4.3 million in 2024, then plummeted by 72.68% to $1.2 million in 2025.
  • Per Business Quant, the three most recent readings for ADPT's Change in Accured Expenses are $1.2 million (Q4 2025), $5.9 million (Q3 2025), and $3.3 million (Q2 2025).